Skip to content

BioArctic is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs.

Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

April 27, 2023

Interim Report Q1 2023

BioArctic AB published the company’s first quarter report for January – March 2023 on Thursday, April 27, 2023, at 08:00 a.m. CET.

Audiocast with teleconference: at 09:30 CEST the same day

For more information, please contact:


Oskar Bosson

Vice President Investor Relations & Communications